trending Market Intelligence /marketintelligence/en/news-insights/trending/32F6C1PWnNgGUAKA3MdkYw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Silence Therapeutics blood disorder drug gets EU orphan drug tag

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Silence Therapeutics blood disorder drug gets EU orphan drug tag

Silence Therapeutics PLC said its SLN124 medicine was granted the orphan drug designation by the European Medicines Agency for treating beta-thalassemia, a blood disorder.

The designation — which grants the therapy expedited clinical development and 10 years of exclusivity if approved — was given by the EMA's Committee for Orphan Medicinal Products.

Beta-thalassemia is an inherited blood disorder that reduces the production of hemoglobin, the protein in red blood cells that transports oxygen throughout the body.

London-based Silence is developing SLN124 for treating iron overload disorders such as beta-thalassemia, myelodysplastic syndrome and hereditary hemochromatosis. Iron overload disorders are characterized by the accumulation of iron in the body.